乳腺癌MRI计算机辅助诊断提取的动力学异质性变化预测新辅助系统治疗的病理反应
回顾性纳入2014至2020年接受新辅助系统治疗及手术的侵袭性乳腺癌患者130例,采用商业计算机辅助诊断系统评估治疗前与治疗中MRI的动力学特征。病理完全缓解组动力学异质性变化(86.14±32.05% vs 8.50±141.01%,p<0.001)和血管体积变化(95.20±14.29% vs 19.89±320.16%,p<0.001)均大于非病理完全缓解组;多因素回归显示动力学异质性变化大(OR=1.030,p<0.001)、年龄(OR=0.931,p=0.005)、孕激素受体阴性(OR=7.831,p=0.001)和HER2阳性(OR=3.455,p=0.017)与病理完全缓解相关。
要点
- 病理完全缓解组治疗前至治疗中MRI的CAD动力学异质性变化大于非病理完全缓解组(p<0.001)。
- 动力学异质性变化大与病理完全缓解独立相关(OR=1.030,p<0.001)。
- CAD提取的动力学异质性可能作为疗效的定量生物标志物。
核心结论
- 乳腺癌治疗前与治疗中MRI之间CAD提取的动力学异质性变化越大,与新辅助系统治疗后病理完全缓解相关。
研究设计与样本
- 回顾性评估2014至2020年连续接受新辅助系统治疗及手术的侵袭性乳腺癌患者130例(平均年龄55岁),使用商业CAD系统评估治疗前和治疗中MRI的动力学特征,以病理完全缓解为参考标准。
诊断标准与关键数值
- 病理完全缓解37例(28.5%);病理完全缓解组较非病理完全缓解组动力学异质性变化86.14±32.05% vs 8.50±141.01%(p<0.001),血管体积变化95.20±14.29% vs 19.89±320.16%(p<0.001);多因素回归中动力学异质性变化大OR=1.030(p<0.001)、年龄OR=0.931(p=0.005)、孕激素受体阴性OR=7.831(p=0.001)、HER2阳性OR=3.455(p=0.017)与病理完全缓解相关。
临床应用与阅片要点
- 作者认为CAD提取的动力学异质性可能作为疗效的定量生物标志物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate whether the computer-aided diagnosis (CAD)-extracted kinetic heterogeneity of breast cancer on MRI and changes therein during treatment were associated with the pathological response to neoadjuvant systemic therapy (NST).
MATERIALS AND METHODS: Consecutive patients with invasive breast cancer, who underwent NST followed by surgery between 2014 and 2020, were retrospectively evaluated. Using a commercial CAD system, kinetic features (angiovolume, peak enhancement, delayed enhancement profiles, and kinetic heterogeneity) of breast cancer were assessed with pre- and mid-treatment MRI. Multivariate logistic regression was used to identify the associations between CAD-extracted kinetic features and pathological complete response (pCR).
RESULTS: A total of 130 patients (mean age, 55 years) were included, 37 (28.5%) of whom achieved a pCR. When the pre- and mid-treatment MRI data were compared, the pCR group exhibited greater changes in kinetic heterogeneity (86.14 ± 32.05% vs. 8.50 ± 141.01%, p < 0.001) and angiovolume (95.20 ± 14.29% vs. 19.89 ± 320.16%; p < 0.001) than the non-pCR group. Multivariate regression analysis showed that a large change in kinetic heterogeneity (odds ratio (OR) = 1.030, p < 0.001), age (OR = 0.931, p = 0.005), progesterone receptor negativity (OR = 7.831, p = 0.001), and HER2 positivity (OR = 3.455, p = 0.017) were associated with pCR.
CONCLUSIONS: A greater change in the CAD-extracted kinetic heterogeneity of breast cancer between pre- and mid-treatment MRI was associated with a pCR in patients on NST.
KEY POINTS: A greater change in kinetic heterogeneity was associated with a pathological complete response. Computer-aided diagnosis-extracted kinetic heterogeneity might serve as a quantitative biomarker of therapeutic efficacy.
引用
- Hwangbo, Kim, Kim, et al. Changes in kinetic heterogeneity of breast cancer via computer-aided diagnosis on MRI predict the pathological response to neoadjuvant systemic therapy. Eur Radiol. 2022. PMID: 35849178. doi:10.1007/s00330-022-08998-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。